158 related articles for article (PubMed ID: 32294127)
1. Efficacy of adjuvant chemotherapy with S-1 in stage II oral squamous cell carcinoma patients: A comparative study using the propensity score matching method.
Yoshida R; Nagata M; Hirosue A; Kawahara K; Nakamoto M; Hirayama M; Takahashi N; Matsuoka Y; Sakata J; Nakashima H; Arita H; Hiraki A; Shinohara M; Kikuchi K; Nakayama H
PLoS One; 2020; 15(4):e0231656. PubMed ID: 32294127
[TBL] [Abstract][Full Text] [Related]
2. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
[TBL] [Abstract][Full Text] [Related]
3. Survival Impact of Surgical Resection in Locally Advanced T4b Oral Squamous Cell Carcinoma.
Gangopadhyay A; Bhatt S; Nandy K; Rai S; Rathod P; Puj KS
Laryngoscope; 2021 Jul; 131(7):E2266-E2274. PubMed ID: 33459389
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study.
Kubota A; Nakatani E; Tsukahara K; Hasegawa Y; Takemura H; Terada T; Taguchi T; Nagahara K; Nakatani H; Yoshino K; Higaki Y; Iwae S; Beppu T; Hanamure Y; Tomita K; Kohno N; Kawabata K; Teramukai S; Fujii M;
PLoS One; 2018; 13(6):e0198391. PubMed ID: 29883463
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcomes of squamous cell carcinoma of the oral cavity in young adults.
Gamez ME; Kraus R; Hinni ML; Moore EJ; Ma DJ; Ko SJ; Rwigema JCM; McGee LA; Halyard MY; Buras MR; Foote RL; Patel SH
Oral Oncol; 2018 Dec; 87():43-48. PubMed ID: 30527242
[TBL] [Abstract][Full Text] [Related]
6. Oral Cancer in the Indian Subcontinent-Survival Outcomes and Risk Factors with Primary Surgery.
Thakar A; Thakur R; Kakkar A; Malhotra RK; Singh CA; Sikka K; Kumar R; Pramanik R; Biswas A; Bhalla AS; Bhaskar S; Sharma A
Laryngoscope; 2021 Oct; 131(10):2254-2261. PubMed ID: 33797083
[TBL] [Abstract][Full Text] [Related]
7. 'Doing as little as possible and as much as necessary' - Oncological efficacy of marginal mandibulectomy in resection of oral cavity cancers.
Suresh S; Thomas S; Janardhan D; Patil S; George NA; Varghese BT; Iype EM; Rafi M; George CK
Oral Oncol; 2019 Aug; 95():91-94. PubMed ID: 31345400
[TBL] [Abstract][Full Text] [Related]
8. The role of adjuvant treatment in early-stage oral cavity squamous cell carcinoma: An international collaborative study.
Fridman E; Na'ara S; Agarwal J; Amit M; Bachar G; Villaret AB; Brandao J; Cernea CR; Chaturvedi P; Clark J; Ebrahimi A; Fliss DM; Jonnalagadda S; Kohler HF; Kowalski LP; Kreppel M; Liao CT; Patel SG; Patel RS; Robbins KT; Shah JP; Shpitzer T; Yen TC; Zöller JE; Gil Z;
Cancer; 2018 Jul; 124(14):2948-2955. PubMed ID: 29757457
[TBL] [Abstract][Full Text] [Related]
9. A histopathological evaluation and potential prognostic implications of oral squamous cell carcinoma with adverse features.
Chang WC; Chang CF; Li YH; Yang CY; Su RY; Lin CK; Chen YW
Oral Oncol; 2019 Aug; 95():65-73. PubMed ID: 31345396
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
[TBL] [Abstract][Full Text] [Related]
11. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study.
Liang L; Ding Y; Yu Y; Liu K; Rao S; Ge Y; Zeng M
BMC Med Imaging; 2021 Apr; 21(1):75. PubMed ID: 33902469
[TBL] [Abstract][Full Text] [Related]
12. Prognostic determinants of locally advanced buccal mucosa cancer: Do we need to relook the current staging criteria?
Pillai V; Yadav V; Kekatpure V; Trivedi N; Chandrashekar NH; Shetty V; Rangappa V; Subramaniam N; Bhat V; Raghavan N; Kolur T; George N; Thomas T; Kuriakose MA
Oral Oncol; 2019 Aug; 95():43-51. PubMed ID: 31345393
[TBL] [Abstract][Full Text] [Related]
13. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study.
Kim IH; Park SS; Lee CM; Kim MC; Kwon IK; Min JS; Kim HI; Lee HH; Lee SI; Chae H
Ann Surg Oncol; 2018 May; 25(5):1176-1183. PubMed ID: 29450755
[TBL] [Abstract][Full Text] [Related]
16. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.
Yoshikawa T; Terashima M; Mizusawa J; Nunobe S; Nishida Y; Yamada T; Kaji M; Fukushima N; Hato S; Choda Y; Yabusaki H; Yoshida K; Ito S; Takeno A; Yasuda T; Kawachi Y; Katayama H; Fukuda H; Boku N; Sano T; Sasako M
Lancet Gastroenterol Hepatol; 2019 Mar; 4(3):208-216. PubMed ID: 30679107
[TBL] [Abstract][Full Text] [Related]
17. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and prognosis of primary treatment-naïve oral cavity squamous cell carcinoma in Norway, a descriptive retrospective study.
Bjerkli IH; Jetlund O; Karevold G; Karlsdóttir Á; Jaatun E; Uhlin-Hansen L; Rikardsen OG; Hadler-Olsen E; Steigen SE
PLoS One; 2020; 15(1):e0227738. PubMed ID: 31945122
[TBL] [Abstract][Full Text] [Related]
19. S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.
Yokota T; Onozawa Y; Boku N; Hamauchi S; Tsushima T; Taniguchi H; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
Jpn J Clin Oncol; 2011 Dec; 41(12):1351-7. PubMed ID: 21980053
[TBL] [Abstract][Full Text] [Related]
20. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
